1.Alles SRA, Smith PA: Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev 2018, 70(2):315–347.
2.Inoue K, Tsuda M: Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci 2018, 19(3):138–152.
3.van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N: Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014, 155(4):654–662.
4.Smith BH, Torrance N, Bennett MI, Lee AJ: Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007, 23(2):143–149.
5.Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK et al: Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014, 19(6):328–335.
6.Malis JL, Rosenthale ME, Gluckman MI: Animal pharmacology of Wy–16,225, a new analgesic agent. J Pharmacol Exp Ther 1975, 194(3):488–498.
7.Fragen RJ, Caldwell N: Comparison of dezocine (WY 16, 225) and meperidine as postoperative analgesics. Anesth Analg 1978, 57(5):563–566.
8.Wu FX, Pan RR, Yu WF, Liu R: The Anti-Nociception Effect of Dezocine in a Rat Neuropathic Pain Model. Transl Perioper Pain Med 2014, 1(1):5–8.
9.Svensson BA, Alari L, Post C: Repeated intrathecal injections of dezocine produce antinociception without evidence for neurotoxicity in the rat: a study of morphometric evaluation of spinal cord histology. Anesth Analg 1992, 75(3):392–399.
10.Li NN, Huang YQ, Huang LE, Guo SH, Shen MR, Guo CL, Zhu SM, Yao YX: Dezocine Antagonizes Morphine Analgesia upon Simultaneous Administration in Rodent Models of Acute Nociception. Pain Physician 2017, 20(3):E401-E409.
11.Ye Z, Zhang M, Ding N, Gao P, Hei Y, Wang Y, Gao W, Ye Q: Antinociceptive effects of dezocine on complete Freund’s adjuvant-induced inflammatory pain in rats. Exp Ther Med 2018, 15(6):5469–5474.
12.Challa SR: Surgical animal models of neuropathic pain: Pros and Cons. Int J Neurosci 2015, 125(3):170–174.
13.Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32(1):77–88.
14.Wu JX, Xu MY, Miao XR, Lu ZJ, Yuan XM, Li XQ, Yu WF: Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. Eur J Pain 2012, 16(10):1378–1388.
15.Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402–408.
16.Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, Lumb BM, Hunt SP: A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci 2009, 29(47):15017–15027.
17.Zhang W, Sun XF, Bo JH, Zhang J, Liu XJ, Wu LP, Ma ZL, Gu XP: Activation of mTOR in the spinal cord is required for pain hypersensitivity induced by chronic constriction injury in mice. Pharmacol Biochem Behav 2013, 111:64–70.
18.Obara I, Tochiki KK, Geranton SM, Carr FB, Lumb BM, Liu Q, Hunt SP: Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. Pain 2011, 152(11):2582–2595.
19.Li G, Lu X, Zhang S, Zhou Q, Zhang L: mTOR and Erk1/2 Signaling in the Cerebrospinal Fluid-Contacting Nucleus is Involved in Neuropathic Pain. Neurochem Res 2015, 40(5):1053–1062.
20.Cao JL, Ruan JP, Ling DY, Guan XH, Bao Q, Yuan Y, Zhang LC, Song XJ, Zeng YM: Activation of peripheral ephrinBs/EphBs signaling induces hyperalgesia through a MAPKs-mediated mechanism in mice. Pain 2008, 139(3):617–631.
21.Ji RR, Gereau RWt, Malcangio M, Strichartz GR: MAP kinase and pain. Brain Res Rev 2009, 60(1):135–148.
22.Obata K, Noguchi K: MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci 2004, 74(21):2643–2653.
23.Sacerdote P, Mussano F, Franchi S, Panerai AE, Bussolati G, Carossa S, Bartorelli A, Bussolati B: Biological components in a standardized derivative of bovine colostrum. J Dairy Sci 2013, 96(3):1745–1754.
24.Zhang Q, Cao DL, Zhang ZJ, Jiang BC, Gao YJ: Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice. J Neuroinflammation 2016, 13(1):183.
25.de Oliveira CM, Nonato FR, de Lima FO, Couto RD, David JP, David JM, Soares MB, Villarreal CF: Antinociceptive properties of bergenin. J Nat Prod 2011, 74(10):2062–2068.
26.Pandit UA, Kothary SP, Pandit SK: Intravenous dezocine for postoperative pain: a double-blind, placebo-controlled comparison with morphine. J Clin Pharmacol 1986, 26(4):275–280.
27.Wang YX, Mao XF, Li TF, Gong N, Zhang MZ: Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. Sci Rep 2017, 7:43137.
28.Gkogkas C, Sonenberg N, Costa-Mattioli M: Translational control mechanisms in long-lasting synaptic plasticity and memory. J Biol Chem 2010, 285(42):31913–31917.
29.Bao Y, Gao Y, Hou W, Yang L, Kong X, Zheng H, Li C, Hua B: Engagement of signaling pathways of protease-activated receptor 2 and mu-opioid receptor in bone cancer pain and morphine tolerance. Int J Cancer 2015, 137(6):1475–1483.
30.Duan Z, Li J, Pang X, Wang H, Su Z: Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib. Cell Physiol Biochem 2018, 48(1):54–62.
31.Zhang Y, Cai G, Ni X, Sun J: The role of ERK activation in the neuronal excitability in the chronically compressed dorsal root ganglia. Neurosci Lett 2007, 419(2):153–157.
32.Opree A, Kress M: Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL–1 beta, and IL–6 but not IL–8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000, 20(16):6289–6293.